Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2674-2681

  Greco, F A ^a   Figlin, R ^a   York, M ^a   Einhorn, L ^a   Schilsky, R ^a   Marshall, E M ^a   Buys, S S ^a   Froimtchuk, M J ^a   Schuller, J ^a   Schuchter, L ^a   Buyse, M ^a   Ritter, L ^a   Man, A ^a   Yap, A K ^a  

^a Roche International Clinical Research Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; FLUOROURACIL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFUSION; DEPRESSION; DIARRHEA; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 10144247244     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2674     Document Type: Article

References (57)

1. Findlay M, Hill A, Cunningham D, et al: Protracted venous infusion 5-fluorouracil and interferon-α in advanced and refractory colorectal cancer. Ann Oncol 5:239-243, 1994
2. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330:1136-1142, 1994
3. Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988
4. Petrelli N, Douglass HO, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A-prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989
5. Doroshow JH, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990
6. Labianca R, Pancera G, Aitini E, et al: Folinic acid + 5-fiuorouracil (5-FU) versus equidose of 5-FU in advanced colorectal cancer. Phase III study of GISCAD (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 2:673-679, 1991
7. Codacci-Pisanelli G, Franchi F: 5-Fluorouracil modulation in the chemotherapy of colorectal cancer. Ital J Gastroenterol 26:369-376, 1994
8. Lavin P, Mittleman A, Douglas H Jr, et al: Survival and response to chemotherapy for advanced colorectal adenocarcinoma. An Eastern Cooperative Oncology Group report. Cancer 46:1536-1543, 1980
9. Balkwill FR, Taylor-Papandimitriou J, Frantes KH, et al: Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in nude mice. Eur J Cancer 16:569-573, 1980
10. Balkwill FR, Moodi EM, Freedman V, et al: Human interferon inhibits growth of established human breast tumors in nude mice. Int J Cancer 30:231-235, 1982
11. Krown SE, Minzer D, Cunningham-Rundles S, et al: High dose human lymphoblastoid interferon in metastatic colorectal cancer: Clinical results and modification of biologic responses. Cancer Treat Rep 71:39-45, 1987
12. Clark PI, Slevin ML, Reznek RH, et al: Two randomized phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer. Int J Colorectal Dis 2:26-29, 1987
13. Kimato Y: Combined effects of interferons alpha, beta, and gamma on tumor growth in vitro. Can To Kagaku Ryoho 13:302-307, 1986
14. Namba M, Miyoshi T, Kanamori T, et al: Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture. Gann 73:819-824, 1982
15. Miyoshi T, Ogawa S, Kanamori T, et al: Interferon potentiates cytotoxic effects of 5-fluorouracil on cell proliferation of established human cell lines originating from neoplastic tissues. Cancer Lett 17:239-247, 1983
16. Sato M, Yoshida H, Urata M, et al: Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leucocyte interferon on human salivary gland adenocarcinoma cell line in culture. Int J Oral Surg 13:35-44, 1984
17. Elias L, Crissman HA: Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 48:4868-4873, 1988
18. Wadler S, Schwartz EL, Goldman M, et al: Preclinical and clinical studies of 5-fluorouracil (FURA) and recombinant alpha-2a-interferon (IFN) against gastrointestinal (GI) malignancies. Clin Res 36:320, 1988 (abstr 803A)
19. Wadler S, Schwartz EL, Goldman M, et al: Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 7:1769-1775, 1989
20. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-198, 1972
23. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
24. Cochran WG: Some methods for strengthening the common chi-square tests. Biometrics 10:417-451, 1954
25. Armitage P: Tests for linear trends in proportions and frequencies. Biometrics 11:375-386, 1955
26. Fomasiero A, Daniele O, Ghiotto C, et al: Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer. Tumori 76:385-388, 1990
27. Pazdur R, Ajani JA, Patt YZ, et al: Phase II study of fluorouracil and recombinant interferon alpha-2a in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 8:2027-2031, 1990
28. Huberman M, McClay E, Atkins M, et al: Phase II trial of 5 fluorouracil (5FU) and recombinant interferon-alpha-2a (IFN) in advanced colorectal cancer. Proc Am Soc Clin Oncol 10:153, 1991 (abstr 478)
29. Weh JH, Platz D, Braumann D, et al: Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma. Eur J Cancer 28A: 1820-1823, 1992
30. Pazdur R, Ajani JA, Patt YZ, et al: Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer 71:1214-1218, 1993
31. Hill M, Norman A, Cunningham D, et al: Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 13:1297-1302, 1995
32. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
33. Wadler S, Wiernick PH: Clinical updates on the role of fluorouracil and recombinant interferon alpha-2a in the treatment of colorectal carcinoma. Serim Oncol 17:16-21, 1990
34. Wadler S, Lembersky B, Atkins M, et al: Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 9:1806-1810, 1991
35. Corfu-A Study Group: Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13:921-928, 1995
36. Cellerino R, Francini G, Del-Papa M, et al: A randomized study of fluorouracil (5FU) with or without alpha-interferon (IFN) in advanced colorectal cancer. Proc Am Soc Clin Oncol 13:A654, 1994 (abstr)
37. Rao F, Cassini J, Niepomniszcze J, et al: 5-Fluorouracil (5FU) vs 5FU and high-dose folinic acid (HDFA) vs 5FU and alpha 2b interferon (IFN) in advanced colorectal cancer (ACC): A phase II randomized trial. Ann Oncol 5:146, 1994 (suppl 5, abstr 298)
38. Hill M, Norman A, Cunningham D, et al: Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 13:2317-2323, 1995
39. Martoni A, Bidin L, Zamagni C, et al: Failure to increase 5-fluorouracil activity with interferon-α2a in the treatment of advanced colorectal cancer. Eur J Cancer 31A:127, 1995 (abstr)
40. Brohée D: Do interferon-alpha or cisplatin add efficacy to 5-fluorouracil regimens in metastatic colo-rectal cancer? Med Sci Res 22:503-504, 1994
41. Atzpodien J, Kirchner H, Hänninen EL, et al: Treatment of metastatic colorectal cancer patients with 5-fluorouracil in combination with recombinant subcutaneous human interleukin-2 and alpha-interferon. Oncology 51:273-275, 1994
42. Ridolfi R, Maltoni R, Riccobon A, et al: A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon. J Chemother 6:265-271, 1994
43. Balaban EP, Ruud C, Arrambide K, et al: Sequential methotrexate, high-dose leucovorin, 5-fluorouracil and interferon for advanced colorectal carcinoma: A phase II trial of 5-fluorouracil "triple modulation." Proc Am Soc Clin Oncol 13:A600, 1994 (abstr)
44. Kemeny N, Younes A, Seiter K, et al: Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 66:2470-2475, 1990
45. Iigo M, Chapekar MS, Blazer RI: Synergistic antitumor effect of fluoropyrimidines and polinosinic-polycytidylic acid against L1210 leukemia. Cancer Res 45:4039-4042, 1985
46. Stolfi RL, Martin DS: Modulation of chemotherapeutic drug activity with polyribonucleotides or with interferon. J Biol Res Mod 4:634-639, 1985
47. Neefe JR, John W: Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors. Semin Oncol 18:77-82, 1991
48. Wadler S, Schwartz EL: Modulation of the activity of cytotoxic drugs by interferons in the treatment of cancer. Onkologie 15:6, 1992 (abstr L-10)
49. Kubota T, Inada T, Ogata Y: Interferon alpha-2a shows antitumor activity in combination with 5-fluorouracil against human colon carcinoma xenografts: A study in reference to thymidylate synthetase activity inhibition. Jpn J Surg 22:481-483, 1992
50. Peters GJ, van der Wilt CL, van Groeningen CJ, et al: Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil. J Clin Oncol 12:2035-2042, 1994
51. Kase S, Kubota T, Watanabe M, et al: Recombinant human interferon alpha-2a increases 5-fluorouracil efficacy by elevating fluorouridine concentration in tumor tissues. Anticancer Res 14:1155-1160, 1994
52. Gamelin E, Maillart P, Dumesnil Y, et al: Influence of plasma pharmacokinetics of 5FU on the response to the treatment in colorectal cancer. Eur J Cancer 2:S83, 1991 (suppl 27, abstr 481)
53. Patel N, Joel SP, Seymour MT, et al: Lack of pharmacokinetic interaction when interferon-α2A is added to a combination of 5-fluorouracil and folinic acid. Proc Am Soc Clin Oncol 11:134, 1992 (abstr 358)
54. Czejka MJ, Jäger W, Schüller J, et al: Clinical pharmacokinetics of 5-fluorouracil: Influence of the biomodulating agents interferon, dipyridamole and folinic acid alone and in combination. Arzneimittelforschung 43:387-390, 1993
55. Danhauser LL, Freimann JH Jr, Gilchrist TL, et al: Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 11:751-761, 1993
56. Sparano JA, Wadler S, Diasio RB, et al: Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: Evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 11:1609-1617, 1993
57. Seymour MT, Patel N, Johnston A, et al: Lack of effect of interferon α-2a upon fluorouracil pharmacokinetics. Br J Cancer 70:724-728, 1994